Initial Diagnostic Workup for Acute Myeloid Leukemia (AML) in Adult Patients

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) initial evaluation includes:

CBC, complete blood count; CT, computed tomography; FISH, fluorescent in situ hybridization; HCT, hematopoietic stem cell transplant; HLA, human leukocyte antigen; LP, lumbar puncture; MRI, magnetic resonance imaging; MUGA, multigated acquisition; PET, positron emission tomography; PT, prothrombin time; PTT, partial thromoplastin time.
aThe WHO 2016 classification defines acute leukemia as ≥20% blasts in the marrow or blood. In an appropriate clinical setting, a diagnosis of AML may be made with less than 20% in patients with the following cytogenetic abnormalities: t(15;17), t(8;21), t(16;16), inv(16). AML evolving from MDS (AML-MDS) is often more resistant to cytotoxic chemotherapy than AML that arises without antecedent hematologic disorder and may have a more indolent course. Some clinical trials designed for high-grade MDS may allow enrollment of patients with AML-MDS.

Reference: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.3.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed April 22, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.